Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
OncoMed Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00744562
First received: August 29, 2008
Last updated: October 10, 2012
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2012
  Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)